> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Cimerli as Generic Lucentis
- URL: https://www.fdaweb.com/fda-approves-cimerli-as-generic-lucentis/
- Published: 2022-08-03T12:00:00.000Z
- Updated: 2026-09-14T17:54:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152436

FDA has approved Coherus’ Cimerli (ranibizumab-eqrn) as the only interchangeable biosimilar to Genentech’s Lucentis for all five indications, with 12 months of interchangeability exclusivity. Coherus [says](https://investors.coherus.com/news-releases/news-release-details/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only?ref=fdaweb.com) Cimerli belongs to the anti-VEGF therapy class of biologics that has been “revolutionary” in helping retinal patients maintain or gain vision.

Cimerli is indicated to treat patients with wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.